Quantcast

Latest Anxiolytics Stories

Insomnia Runs In The Family
2011-09-12 09:44:25

  A study presented today by Université Laval researchers at the 4th World Congress on Sleep Medicine currently underway in Quebec City revealed that the risk of insomnia is 67% higher in people from families in which at least one member is an insomniac. The research team, directed by Dr. Charles M. Morin of Université Laval's School of Psychology, came to these conclusions following a study involving 3,485 people. The participants were asked to answer a...

2011-08-16 13:34:37

Compared with oral corticosteroids, use of the beta-blocker propranolol for treatment of infantile hemangiomas (IHs) was associated with higher rates of lesion clearance, fewer adverse effects, fewer surgical interventions after treatment, and lowers cost, according to a report published Online First by Archives of Dermatology, one of the JAMA/Archives journals. A common type of vascular tumor, IH tends to grow rapidly during the first three to 12 months of age, and then slowly and...

2011-07-28 15:05:00

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2011. For the second quarter of 2011, the Company reported net income of $2.0 million, or $0.04 per share, compared to a net loss of $5.2 million, or $0.09 loss per share, for the same period in 2010. For the six months ended June 30, 2011, the Company reported net income of $4.9 million, or $0.09 per share, as compared to a net loss of...

2011-07-15 19:02:00

POINT RICHMOND, Calif., July 15, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today plans to reduce operating expenses by eliminating approximately 45% of its workforce following notification from the U.S. Food and Drug Administration (FDA) that the resubmitted New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet), the company's lead product candidate, cannot be approved in its present form....

2011-07-14 22:42:00

POINT RICHMOND, Calif., July 14, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). In the Complete Response Letter, the FDA confirmed that Transcept has adequately demonstrated that Intermezzo® is efficacious for use...

2011-07-13 11:45:00

WASHINGTON, July 13, 2011 /PRNewswire-USNewswire/ -- This week's report on corn and other grains by the U.S. Department of Agriculture marks an important turning point in the evolution of agriculture, according to the National Chicken Council: for the first time, the government is predicting that more corn will be used in this crop year for motor fuel than used for animal feed to help produce food for people. "Raising poultry and livestock as food for people is taking second place to...

2011-07-12 19:02:00

POINT RICHMOND, Calif., July 12, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it expects to receive a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet) on or before July 14, 2011, the PDUFA date assigned by the FDA for completion of the Intermezzo® NDA review. The FDA issues a...

2011-07-07 05:30:00

ANAHEIM, Calif., July 7, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release second quarter 2011 financial results on Tuesday, July 26, 2011 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, July 26, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the second quarter, as well as current corporate developments. Conference call details:...

2011-06-24 05:10:00

EXTON, Pa., June 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related